secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-08-10T13:45:14+00:00
Accession:  0001493152-26-036777
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma completes $30M acquisition of Dura Driver Control Systems
--------------------------------------------------------------------------

- Acquired 100% of DCS for ~$30.0M cash; DCS becomes wholly owned subsidiary on Aug 6, 2026.
- DCS FY2025 revenue $209.5M and Adjusted EBITDA $22.3M; H1 2026 revenue $103.9M, EBITDA $10.5M.
- Entered $22.5M senior secured revolving credit facility to fund acquisition, along with cash on hand.
- Issued $3.75M convertible notes for $3.0M (20% OID), conversion at $8.00/share for working capital.
- DCS CEO Hans Vorstenbosch stays; 11 plants, 310+ patents, 50+ customers, top-10 OEM avg 28-yr relationship.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226036777/0001493152-26-036777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226036777/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer